PLASMA CELL MYELOMA

This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…

This study looked at 42 people with multiple myeloma that was still present after a stem cell transplant. It compared continuing lenalidomide alone versus adding two other drugs (ixazomib and dexamethasone) to try to eliminate the remaining cancer. The goal was to see which appro…

This study tested whether giving two drugs—ixazomib and lenalidomide—in an alternating schedule after a stem cell transplant could safely delay the return of multiple myeloma. Thirty patients who had already received a transplant took part. The main goal was to check for side eff…

This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one tha…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This early-stage trial tested an experimental drug called SAR442085 in 37 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and check for any signs that the drug shrinks tumors. Participants received …

This study tested whether giving Darzalex Faspro (a drug for multiple myeloma) at home is practical and satisfactory for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The main goal was to measure…

This study tested whether a battery-powered drill could make bone marrow biopsies less painful and produce better samples than the traditional manual needle. 100 patients with plasma cell disorders took part. Researchers measured pain levels and the quality of the biopsy sample.

This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have serious side effects from chemotherapy. The goal is…